Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia

Inclusion Criteria:

• Adults aged ≥ 18 years

• A clinical diagnosis of persistent or chronic ITP, as defined by a history ofplatelet counts <50 x 109/L on two occasions in the preceding 3 to 12 months or >12months, respectively, and documented response to at least 1 prior ITP-directedtherapy. ITP-directed therapies include corticosteroids, intravenous immuneglobulin, Rho(D) immune globulin, splenectomy, thrombopoietin receptor agonists, andfostamatinib. Other qualifying agents used for the treatment of ITP are permissiblewith approval of the principal investigator.

• Ability to follow instructions in English.

Exclusion Criteria:

• Pre-existing diagnosis of cognitive impairment from dementia, stroke, or otherneurologic disease.

• Active psychiatric disorder, defined as uncontrolled major depression,schizophrenia, severe anxiety, or active alcohol or drug abuse.

• Active malignancy, requiring or likely to require chemotherapeutic or surgicaltreatment, except for non-melanoma skin cancer.

• Brain tumor or cranial surgery within the past year.

• Significant hearing or vision impairment that would preclude the ability to completeneurocognitive testing via a virtual platform.